In breast cancer cells, mTORC1 activates SREBP-2 to promote lipogenesis, cell growth, proliferation and survival that can be ablated with mTOR inhibitors, linking mTORC1 control to SREBP-2 signaling [26]. Here, SREBF2 is linked to breast carcinoma.